Loading...
Market
Novavax announce new Phase 3 trial for influenza vaccine by June 30, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Novavax press releases and clinical trial registries
Story
Novavax (NVAX) Shares Plunge 20% as FDA Halts Phase 3 COVID-Flu Vaccine Trials Over Motor Neuropathy
Oct 16, 2024, 02:17 PM
Novavax (NASDAQ: NVAX) announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its Investigational New Drug (IND) applications for both its COVID-19-influenza combination vaccine and its stand-alone influenza vaccine candidates in Phase 3 trials. The hold is due to safety concerns following a spontaneous report of a serious adverse event (SAE) of motor neuropathy in a trial participant. Following the news on Wednesday, shares of Novavax plunged by up to 20%, with the stock dropping as much as 18.7% during trading.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Hold lifted with no conditions • 25%
Hold lifted with conditions • 25%
Hold extended • 25%
Hold converted to permanent suspension • 25%
Positive • 33%
Neutral • 33%
Negative • 33%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
